SanyouBio Launches Comprehensive Suite of 73 Bispecific Antibody Reference Products to Accelerate Drug Development
核心洞察
SanyouBio (搜索) has introduced 73 bispecific antibody reference products covering all approved and major clinical-stage bispecific antibody drugs, marking a significant advancement in drug development support.
The global bispecific antibody drug market is projected to achieve a 37.5% CAGR from 2024 to 2033, demonstrating the growing importance of this therapeutic approach.
The company's OneClick+ platform, featuring over 150 antibody configuration diagrams, provides integrated support for bispecific antibody design and development.
SanyouBio (搜索) announced a major advancement in bispecific antibody drug development with the launch of 73 comprehensive reference antibody products. This extensive portfolio, released on March 5, 2025, encompasses all globally approved bispecific antibody drugs and key candidates in clinical development, providing crucial tools for researchers and drug developers.
The reference products span multiple bispecific antibody configurations, including CrossMab (搜索), Duobody (搜索), BiTE (搜索), DRAT (搜索), and Fab (搜索) platforms. Each product has undergone extensive quality control and validation to ensure optimal binding affinity and stability characteristics, making them suitable for both early-stage drug screening and preclinical efficacy evaluation.
Market Growth and Therapeutic Potential
The bispecific antibody sector represents one of the most dynamic areas in modern drug development. These innovative therapeutics can simultaneously target two different antigens or epitopes, potentially offering superior efficacy compared to traditional monoclonal antibodies. This dual-targeting approach helps address key challenges in current therapies, particularly in overcoming drug resistance associated with single-target treatments.
Market analysis from Market.us indicates robust growth potential, with the global bispecific antibody drug market expected to expand at a compound annual growth rate of 37.5% from 2024 to 2033. By the end of 2024, 19 bispecific antibody drugs had received global regulatory approval, with hundreds more in various stages of development.
Technical Innovation and Support Platform
Complementing the reference product launch, SanyouBio (搜索) has developed OneClick+, an advanced bispecific design application. This comprehensive platform integrates more than 150 antibody configuration diagrams across four major categories: classic bispecific antibodies, nanobodies, ScFv, and complex antibodies. The system aims to streamline the personalized design process for bispecific antibody drugs.
"This product launch represents a significant milestone in our commitment to advancing bispecific drug development," stated Dr. Lang Guojun, CEO of SanyouBio (搜索). "We are dedicated to supporting the global biopharmaceutical industry through continued research and innovation in this field."
Future Development Plans
SanyouBio (搜索) has outlined plans to expand its bispecific antibody reference product portfolio further and enhance the capabilities of the OneClick+ platform. These initiatives align with the company's mission to facilitate more efficient and effective bispecific antibody drug development.
The company's comprehensive approach, combining reference products with advanced design tools, positions it to address the growing demand for bispecific antibody therapeutics. This integrated solution aims to accelerate the development timeline from concept to clinical application, potentially bringing innovative treatments to patients more rapidly.